74.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$75.11
Aprire:
$74.41
Volume 24 ore:
2.34M
Relative Volume:
0.54
Capitalizzazione di mercato:
$44.68B
Reddito:
$5.54B
Utile/perdita netta:
$4.18B
Rapporto P/E:
10.70
EPS:
7
Flusso di cassa netto:
$259.90M
1 W Prestazione:
-1.78%
1M Prestazione:
+8.02%
6M Prestazione:
+13.95%
1 anno Prestazione:
-11.95%
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Confronta EW con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
EW
Edwards Lifesciences Corp
|
74.92 | 44.68B | 5.54B | 4.18B | 259.90M | 7.00 |
![]()
ABT
Abbott Laboratories
|
133.06 | 227.05B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
104.12 | 152.00B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
377.52 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
82.32 | 108.50B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
2024-09-18 | Downgrade | Jefferies | Buy → Hold |
2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
2024-07-25 | Downgrade | Truist | Buy → Hold |
2024-05-30 | Iniziato | Goldman | Buy |
2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
2023-07-19 | Iniziato | Robert W. Baird | Outperform |
2023-05-30 | Ripresa | Morgan Stanley | Overweight |
2023-03-29 | Iniziato | UBS | Neutral |
2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
2022-12-06 | Downgrade | Stifel | Buy → Hold |
2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
2022-10-26 | Iniziato | Mizuho | Buy |
2022-10-18 | Iniziato | Barclays | Overweight |
2022-10-12 | Iniziato | Jefferies | Buy |
2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
2022-04-13 | Iniziato | Truist | Buy |
2022-04-06 | Iniziato | Wolfe Research | Outperform |
2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
2022-03-02 | Ripresa | BofA Securities | Neutral |
2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
2022-01-27 | Reiterato | Citigroup | Buy |
2022-01-27 | Reiterato | Evercore ISI | Outperform |
2022-01-27 | Reiterato | Raymond James | Outperform |
2022-01-27 | Reiterato | Stifel | Buy |
2022-01-27 | Reiterato | UBS | Neutral |
2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2021-07-30 | Reiterato | Canaccord Genuity | Buy |
2021-07-30 | Reiterato | Deutsche Bank | Hold |
2021-07-30 | Reiterato | Jefferies | Buy |
2021-07-30 | Reiterato | Morgan Stanley | Overweight |
2021-07-30 | Reiterato | Oppenheimer | Outperform |
2021-07-30 | Reiterato | Stifel | Buy |
2021-07-30 | Reiterato | UBS | Neutral |
2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
2021-05-25 | Iniziato | Barclays | Overweight |
2021-04-15 | Iniziato | Atlantic Equities | Neutral |
2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
2020-12-11 | Reiterato | Canaccord Genuity | Buy |
2020-09-11 | Iniziato | Wolfe Research | Underperform |
2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2020-03-05 | Iniziato | Citigroup | Buy |
2020-02-13 | Iniziato | Goldman | Neutral |
2020-02-06 | Ripresa | BTIG Research | Neutral |
2020-01-10 | Iniziato | Oppenheimer | Outperform |
2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
2019-10-24 | Reiterato | Canaccord Genuity | Buy |
2019-09-23 | Iniziato | Piper Jaffray | Overweight |
2019-07-24 | Reiterato | BofA/Merrill | Buy |
2019-03-18 | Reiterato | Canaccord Genuity | Buy |
2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2019-01-03 | Iniziato | Deutsche Bank | Hold |
2018-11-28 | Iniziato | UBS | Neutral |
2018-10-16 | Iniziato | Barclays | Underweight |
2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com
Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace
FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India
FDA Approves First-Ever TAVR Treatment for Asymptomatic Aortic Stenosis Patients - Stock Titan
Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey
Commit To Purchase Edwards Lifesciences At $60, Earn 6.8% Using Options - Nasdaq
Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript - Insider Monkey
Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks
Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook BrightensEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance
Edwards Lifesciences Corp (EW) Shares Up 7.25% on Apr 24 - GuruFocus
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Stifel maintains Edwards Lifesciences stock with $90 target - Investing.com
Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78 - marketscreener.com
Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize
Edwards Lifesciences (EW) Price Target Raised by Baird Amid Mixed Q1 Results | EW Stock News - GuruFocus
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised - Yahoo Finance
Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, T - GuruFocus
Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, Target Raised | EW Stock News - GuruFocus
Piper Sandler raises Edwards Lifesciences stock to Overweight - Investing.com
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast - Investing.com
Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast By Investing.com - Investing.com UK
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Milestones - GuruFocus
Edwards Lifesciences (EW) Reports Strong Q1 2025 Growth on Cardi - GuruFocus
Edwards Lifesciences Reports Strong Q1 Growth - TipRanks
Edwards posts Street-beating Q1 results, ups 2025 sales guidance - MassDevice
Edwards Lifesciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Edwards Lifesciences Corp Q1 2025 Earnings: EPS of $0.62 Beats E - GuruFocus
Edwards Lifesciences raises 2025 sales forecast after robust quarter - marketscreener.com
Edwards Lifesciences Q1 Adjusted Earnings, Sales Rise; Provides Q2 Guidance - marketscreener.com
Innovative Strategy Boosts Edwards Lifesciences (EW) Q1 Revenue Above Expectations | EW Stock News - GuruFocus
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat - MSN
Edwards Lifesciences Reports First Quarter Results - TradingView
Edwards Lifesciences Corp. Reveals Climb In Q1 Profit - Nasdaq
Earnings Flash (EW) Edwards Lifesciences Reports Q1 Adjusted EPS $0.64, vs. FactSet Est of $0.60 - marketscreener.com
Edwards Lifesciences Crushes Q1 Expectations: TMTT Sales Surge 58%, New SAPIEN M3 Approval Fuels Growth - Stock Titan
EDWARDS LIFESCIENCES Earnings Preview: Recent $EW Insider Trading, Hedge Fund Activity, and More - Nasdaq
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue - BioSpace
Lobbying Update: $350,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed - Nasdaq
Edwards touts 8-year data for Resilia valve tissue - MassDevice
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus
Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan
Is Edwards Lifesciences Gaining or Losing Market Support?Edwards Lifesciences (NYSE:EW) - Benzinga
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):